Kawasaki, Kenta
Rekhtman, Natasha
Quintanal-Villalonga, Álvaro http://orcid.org/0000-0002-7234-3446
Rudin, Charles M. http://orcid.org/0000-0001-5204-3465
Article History
Accepted: 29 September 2022
First Online: 28 October 2022
Competing interests
: C.M.R. has consulted regarding oncology drug development for AbbVie, Amgen, AstraZeneca, D2G, Daiichi Sankyo, Epizyme, Genentech/Roche, Ipsen, Jazz, Kowa, Lilly, Merck and Syros, and serves on the scientific advisory boards of Bridge Medicines, Earli, and Harpoon Therapeutics. The other authors declare no competing interests.